Skip to main content

Leukopenia

3
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
1 program
1
PosaconazolePhase 3Small Molecule
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
PosaconazolePhase 3Small Molecule1 trial
Active Trials
NCT00811928Completed252Est. May 2010
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
MozobilPhase 1/21 trial
Active Trials
NCT00967785Recruiting20Est. Dec 2026
Tasso
TassoWA - Seattle
1 program
Tasso+ CBCN/A1 trial
Active Trials
NCT06360952Not Yet Recruiting40Est. Aug 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sharp TherapeuticsPosaconazole
Allergy TherapeuticsMozobil
TassoTasso+ CBC

Clinical Trials (3)

Total enrollment: 312 patients across 3 trials

Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)

Start: Nov 2008Est. completion: May 2010252 patients
Phase 3Completed

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

Start: Jan 2010Est. completion: Dec 202620 patients
Phase 1/2Recruiting

A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC

Start: May 2024Est. completion: Aug 202440 patients
N/ANot Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 312 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.